EMR integration dramatically improves customer success with drug diversion monitoring solutions, according to a new KLAS Report. The new report reveals that EMR integration with drug diversion monitoring enables analytics tools to compare drug-use data from the eMAR, not just pharmacy systems. This integration closes the loop on the full medication administration process, improving accuracy, and creating a more complete picture for investigation.
State of Drug Diversion Monitoring Solutions in 2019
Given the increased national focus on the opioid epidemic, there has been a surge in demand for advanced drug diversion monitoring tools. In response to the growing demand, both established and emerging vendors have responded by developing new solutions that promise next-generation technology to comprehensively and proactively monitor dispensing behaviors.
The report, Drug Diversion Monitoring: An Early Look at Emerging vs. Established Technology offers an in-depth look at today’s current state of drug diversion monitoring solutions including feedback on the customer experience. As it stands today, only a few customers feel they are having a next-generation experience with their drug diversion monitoring solution.
Omnicell Analytics Emerges As The Most-Adopted Solution
Omnicell Analytics is the emerging solution with the most adoption (mostly from former Pandora Analytics clients). However, Omnicell Analytics customers with EMR integration report having more comprehensive visibility into dispensing behavior. Because EMR integration costs extra, a significant number of customers do not have it and resort to manual processes resulting in a higher number of false positives. Omnicell’s Pandora customers tend to be more satisfied than Omnicell Analytics customers— though the older system is more manual and less advanced, it still functions as expected.
Medacist RxAuditor Customers Report Dissatisfaction with Manual Investigation Workflows
Medacist RxAuditor clients report dated technology and clunky investigation workflows as key issues hindering effective drug diversion monitoring. As the largest vendor in the market, Medacist offers several tools intended to provide advanced capabilities; however, very few respondents report having or using these tools. Medacist RxAuditor clients report lengthy reports and abnormal behaviors since their system relies solely on dispensing data from cabinets and carousels.
Other key findings of the report:
– Other emerging options are also getting consideration, though adoption to date is limited.
– Kit Check has expanded on their existing kit/tray management customer base with their new drug diversion monitoring solution, Bluesight for Controlled Substances; to date, fewer than 20 organizations are live on the solution.
– BD’s new offering—HealthSight Diversion Management—has potential for high adoption given BD’s existing pharmacy customer base.
– Without existing pharmacy customers, new third-party entrants HelioMetrics, Invistics, and Protenus (each with a handful of live customers) face bigger adoption hurdles since most pharmacies are looking to consolidate to fewer vendors to improve integration.
